These findings suggest that intravesical XUC treatment modulates the immune cell tumor microenvironment, except the CD68+ cell, which showed no significant difference between all treatments and the vehicle control group (Figure 4E) since monocytes could play a dual role in both pro- and antitumoral immunity during tumor progression [24]. This evidence concerns the gene CD68 and neoplasm.